2. Search Result
Search Result
Results for "

nucleocytoplasmic

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Biochemical Assay Reagents

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-170316
    Ibetazol

    		Ras Cancer
    Ibetazol is a Importin β1 (KPNB1) inhibitor and nucleocytoplasmic transport disruptor. Ibetazol binds covalently to Cys585 of Importin β1, blocks both Importin β1-mediated direct transport and Importin α-dependent nuclear import processes, without affecting transport mediated by other nucleocytoplasmic transport proteins. Ibetazol induces cytoplasmic accumulation of Importin α1, and inhibits nuclear import of substrates carrying nuclear localization signals (NLS), including the NLS-cMyc reporter gene, RelA/p65 and SREBP1. Ibetazol triggers spindle malformation and chromosome misalignment by disrupting the mitotic function of Importin β1. Ibetazol inhibits the proliferation of cells expressing wild-type Importin β1. Ibetazol has a high activity-cytotoxicity window, lacks intrinsic fluorescence, and acts rapidly on nucleocytoplasmic transport processes. Ibetazol serves as a tool compound for investigating nuclear import processes specifically mediated by Importin β1 .
    Ibetazol
  • HY-169325
    (S)-ACE-OH

    		Molecular Glues Cancer
    (S)-ACE-OH is a molecular glue with anticancer activity. (S)-ACE-OH promotes nucleoporin degradation and disruption of nucleocytoplasmic trafficking by inducing the interaction between E3 ubiquitin ligase TRIM21 and nucleoporin NUP98 .
    (S)-ACE-OH
  • HY-13636A
    Fulvestrant (S enantiomer)

    ICI 182780 (S enantiomer); ZD 9238 (S enantiomer); ZM 182780 (S enantiomer)

    		 Drug Isomer Estrogen Receptor/ERR p38 MAPK Apoptosis Cancer
    Fulvestrant (ICI 182780; ZD 9238) S enantiomer is the S-enantiomer of Fulvestrant (HY-13636), a potent estrogen receptor inhibitor. Fulvestrant binds to and blocks the estrogen receptor, promotes its degradation, and thereby inhibits receptor dimerization, nucleocytoplasmic shuttling and transcriptional activity. Fulvestrant effectively blocks estrogen signaling, MAPK pathway activation and ER-regulated protein expression. Fulvestrant induces apoptosis, inhibits the proliferation of breast cancer and prolactinoma cells, and reduces the mineralization level, alkaline phosphatase activity and osteocalcin expression of preosteoblasts. Prenatal exposure to Fulvestrant impairs ovarian follicular development and causes ovarian structural damage. Fulvestrant has been widely used in studies related to breast cancer, prolactinoma and other conditions .
    Fulvestrant (S enantiomer)
  • HY-W039939
    2-Azido-2-deoxy-D-glucose, 98%

    2-ADG, 98%

    		 Biochemical Assay Reagents OGT Cancer
    2-Azido-2-deoxy-D-glucose, 98% (2-ADG, 98%) is a substrate of O-GlcNAc transferase (OGT). 2-Azido-2-deoxy-D-glucose, 98% can be transferred from UDP-GlcAz to proteins in vitro via OGT mediation. When delivered as AcGlcAz, 2-Azido-2-deoxy-D-glucose, 98% enables the labeling and investigation of O-GlcNAc-modified nuclear and cytoplasmic proteins in cells. 2-Azido-2-deoxy-D-glucose, 98% undergoes strain-promoted [3+2] azide-alkyne cycloaddition (SPAAC) with technetium- 99m-labeled dibenzocyclooctyne derivatives in vivo. 2-Azido-2-deoxy-D-glucose, 98% can be used in sarcoma-related research .
    2-Azido-2-deoxy-D-glucose, 98%
  • HY-135785
    OSMI-3

    		OGT Acyltransferase Metabolic Disease
    OSMI-3 (Compound 2b) is a potent, long-lasting, and cell-permeable O-linked N-acetylglucosamine transferase (OGT) inhibitor. Cells contain a large nuclear pool of partially spliced OGT transcript, and OSMI-3 increases detained intron splicing in cells .
    OSMI-3
  • HY-W781148
    Suptopin-2

    		Topoisomerase Cancer
    Sutopin-2 is a topoisomerase II inhibitor. Suptopin-2 affects cell cycle progression and stability of microtubules. Sutopin-2 induces cell cycle arrest by regulating the nucleocytoplasmic transport of cyclin B1 .
    Suptopin-2
  • HY-181541
    HIT211504993

    		HDAC Apoptosis Wnt β-catenin MDM-2/p53 c-Myc Cancer
    HIT211504993 is a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 0.070 μM. HIT211504993 suppresses cancer cell proliferation, cause G1 phase cell cycle arrest and induces apoptosis. HIT211504993 inhibits Myc-driven tumorigenesis via nucleocytoplasmic acetylation, p53 modulation, and Wnt/β-catenin signaling modulation. HIT211504993 inhibits tumor growth in a colon cancer xenograft mouse model. HIT211504993 can be used for the research of colon cancer .
    HIT211504993

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: